Argatroban dosage requirements and outcomes in intensive care versus non-intensive care patients

Pharmacotherapy

Volumn 29, Issue 9, 2009, Pages 1073-1081

  Smythe, Maureen A ^a,b   Koerber, John M ^a   Forsyth, Lisa L ^a   Priziola, Jennifer L ^a   Balasubramaniam, Mamtha ^a   Mattson, Joan C ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Argatroban; Direct thrombin inhibitor; Heparin induced thrombocytopenia; Intensive care unit

Indexed keywords

ARGATROBAN;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTENSIVE CARE UNIT; MALE; MEDICAL RECORD REVIEW; PARTIAL THROMBOPLASTIN TIME; TERTIARY HEALTH CARE; THROMBOSIS; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPARIN; HUMANS; INTENSIVE CARE; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PIPECOLIC ACIDS; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME;

EID: 69249105025     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.9.1073     Document Type: Article

References (18)

1. McKeage K, Plosker GL. Argatroban. Drugs 2001;61(4): 515-522
2. GlaxoSmithKline. Argatroban prescribing information. Research Triangle Park, NC; 2008.
3. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103(14):1838-1843 (Pubitemid 32328395)
4. Verme-Gibboney CN, Hursting MJ. Argatroban dosing in patients with heparin-induced thrombocytopenia. Ann Pharmacother 2003;37(7-8):970-975 (Pubitemid 36875223)
5. Reichert MG, MacGregor DA, Kincaid EH, Dolinski SY. Excessive argatroban anticoagulation for heparin-induced thrombocytopenia. Ann Pharmacother 2003;37(5):652-654 (Pubitemid 36523057)
6. Reddy BV, Grossman EJ, Trevino SA, Hursting MJ, Murray PT. Argatroban therapy in patients with heparin-induced thrombocytopenia requiring renal replacement therapy. Ann Pharmacother 2005;39(10):1601-1605 (Pubitemid 41393115)
7. Williamson DR, Boulanger I, Tardif M, Albert M, Grégoire G. Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction. Pharmacotherapy 2004;24(3): 409-414 (Pubitemid 38298768)
8. Arpino PA, Hallisey RK. Effect of renal function on the pharmacodynamics of argatroban. Ann Pharmacother 2004;38(1):25-29 (Pubitemid 38018000)
9. Beiderlinden M, Treschan TA, Görlinger K, Peters J. Argatroban anticoagulation in critically ill patients. Ann Pharmacother 2007;41(5):749-754 (Pubitemid 46752654)
10. Bartholomew JR, Pietrangeli CE, Hursting MJ. Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients. Drugs Aging 2007;24(6):489-499 (Pubitemid 46974912)
11. Koster A, Buz S, Hetzer R, Kuppe H, Breddin K, Harder S. Anticoagulation with argatroban in patients with heparininduced thrombocytopenia antibodies after cardiovascular surgery with cardiopulmonary bypass: first results from the ARG-E03 trial. J Thorac Cardiovasc Surg 2006;132(3):699-700. (Pubitemid 44278888)
12. Hoffman WD, Czyz Y, McCollum DA, Hursting MJ. Reduced argatroban doses after coronary bypass graft surgery. Ann Pharmacother 2008;42(3):309-316
13. Warkentin TE, Greinacher A, Koster A, Lincoff M. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidenced-based practice guidelines, 8th ed. Chest 2008;133(6):340S-80. (Pubitemid 351892970)
14. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003;163(15):1849-1856 (Pubitemid 36960936)
15. Guzzi LM, McCollum DA, Hursting MJ. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia. J Thromb Thrombolysis 2006;22(3):169-176
16. Kodityal S, Nguyen PH, Kodityal A, Sherer J, Hursting M, Rice L. Argatroban for suspected heparin-induced thrombocytopenia: contemporary experience at a large teaching hospital. J Intensive Care Med 2006;21(2):86-92.
17. Keegan SP, Gallagher EM, Ernst NE, Young EJ, Mueller EW. Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed heparin induced thrombocytopenia. Ann Pharmacother 2009;43(1):19-27.
18. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications, meta-analysis of two prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000;96(3):846-851 (Pubitemid 30616845)